KR100248324B1 - 메토트렉세이트 유도체 - Google Patents

메토트렉세이트 유도체 Download PDF

Info

Publication number
KR100248324B1
KR100248324B1 KR1019940702559A KR19940702559A KR100248324B1 KR 100248324 B1 KR100248324 B1 KR 100248324B1 KR 1019940702559 A KR1019940702559 A KR 1019940702559A KR 19940702559 A KR19940702559 A KR 19940702559A KR 100248324 B1 KR100248324 B1 KR 100248324B1
Authority
KR
South Korea
Prior art keywords
compound
general formula
solution
added
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940702559A
Other languages
English (en)
Korean (ko)
Inventor
히로하루 마쓰오까
히로시 스즈끼
노부아끼 가또
게이이찌로 쓰지
도시오 구로끼
노리아끼 마루야마
가즈야 나까고미
Original Assignee
나가야마 오사무
쥬가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나가야마 오사무, 쥬가이 세이야쿠 가부시키가이샤 filed Critical 나가야마 오사무
Application granted granted Critical
Publication of KR100248324B1 publication Critical patent/KR100248324B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1019940702559A 1992-01-27 1993-01-27 메토트렉세이트 유도체 Expired - Fee Related KR100248324B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP92-53051 1992-01-27
JP5305192 1992-01-27
JP92-75106 1992-02-13
JP7510692 1992-02-13
JP10832092 1992-03-16
JP92-108320 1992-03-16
JP11512692 1992-03-24
JP92-115126 1992-03-24
PCT/JP1993/000096 WO1993015077A1 (fr) 1992-01-27 1993-01-27 Derive de methotrexate

Publications (1)

Publication Number Publication Date
KR100248324B1 true KR100248324B1 (ko) 2000-04-01

Family

ID=27462860

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702559A Expired - Fee Related KR100248324B1 (ko) 1992-01-27 1993-01-27 메토트렉세이트 유도체

Country Status (10)

Country Link
US (2) US6559149B1 (enExample)
EP (1) EP0632038B1 (enExample)
KR (1) KR100248324B1 (enExample)
AT (1) ATE204576T1 (enExample)
AU (1) AU3367693A (enExample)
CA (1) CA2128205C (enExample)
DE (1) DE69330639T2 (enExample)
ES (1) ES2161713T3 (enExample)
TW (1) TW223637B (enExample)
WO (1) WO1993015077A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2161713T3 (es) * 1992-01-27 2001-12-16 Chugai Pharmaceutical Co Ltd Derivado de metotrexato.
AU5715894A (en) * 1992-12-25 1994-07-19 Chugai Seiyaku Kabushiki Kaisha Methotrexate derivative
EP0818199A4 (en) * 1995-03-27 2002-08-14 Chugai Pharmaceutical Co Ltd MEDICINE CONTAINING METHOTREXATE DERIVATIVE
US7276506B2 (en) * 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US20070032477A1 (en) * 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
US7601834B2 (en) * 2005-02-22 2009-10-13 Savvipharm Inc Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
ES2473665T3 (es) 2005-11-28 2014-07-07 Verrow Pharmaceuticals, Inc. Composiciones útiles para reducir la nefrotoxicidad y los métodos de uso de las mismas
WO2007098089A2 (en) * 2006-02-17 2007-08-30 Novacea, Inc. Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009079A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
TR201901010T4 (tr) 2007-04-11 2019-02-21 Merck & Cie 18F etiketli folatlar.
CA2742909C (en) 2008-11-19 2017-12-19 Pola Chemical Industries Inc. Anti-wrinkle agents
SI3321265T1 (sl) 2015-03-04 2020-07-31 Gilead Sciences, Inc. Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
JP6746776B2 (ja) 2016-09-02 2020-08-26 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体調節剤化合物
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490529A (en) * 1983-09-06 1984-12-25 Dana-Farber Cancer Institute, Inc. Cysteic acid and homocysteic acid analogues of methotrexate and aminopterin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI812775L (fi) 1980-09-12 1982-03-13 Farmos Oy Foerfarande foer framstaellning av n-/4-/(2,4-diamino-6-pteridinyl)-metyl/metylamino/benzoyl/glutaminsyra och derivat daerav
CN1032858C (zh) * 1990-08-14 1996-09-25 中外制药株式会社 新颖的甲氨蝶呤衍生物的制造方法
JP3124592B2 (ja) * 1990-08-14 2001-01-15 中外製薬株式会社 新規メトトレキセート誘導体
JP3207285B2 (ja) * 1992-01-27 2001-09-10 中外製薬株式会社 新規メトトレキセート誘導体
ES2161713T3 (es) * 1992-01-27 2001-12-16 Chugai Pharmaceutical Co Ltd Derivado de metotrexato.
JP3274532B2 (ja) * 1992-03-24 2002-04-15 中外製薬株式会社 抗リウマチ剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490529A (en) * 1983-09-06 1984-12-25 Dana-Farber Cancer Institute, Inc. Cysteic acid and homocysteic acid analogues of methotrexate and aminopterin

Also Published As

Publication number Publication date
DE69330639D1 (de) 2001-09-27
CA2128205A1 (en) 1993-08-05
EP0632038A4 (en) 1995-02-22
AU3367693A (en) 1993-09-01
TW223637B (enExample) 1994-05-11
US6559149B1 (en) 2003-05-06
WO1993015077A1 (fr) 1993-08-05
EP0632038A1 (en) 1995-01-04
DE69330639T2 (de) 2002-07-04
ES2161713T3 (es) 2001-12-16
CA2128205C (en) 2004-03-30
US20030171376A1 (en) 2003-09-11
ATE204576T1 (de) 2001-09-15
EP0632038B1 (en) 2001-08-22

Similar Documents

Publication Publication Date Title
KR100248324B1 (ko) 메토트렉세이트 유도체
US5583239A (en) Antimicrobial sterol conjugates
CN102250189A (zh) 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途
JPS6399079A (ja) 新規セフェム化合物およびその製造法
JP2021521190A (ja) 重水素化アミド及び重水素化スルホンアミドを合成する新規な方法
JPH10182583A (ja) 新規ヒドロキサム酸誘導体
CN101967105A (zh) 具有抗癌活性的β-羟基保护的双癸基季铵盐及制备方法
EP0580812A1 (en) Anti-tumor and anti-psoriatic agents
JPWO2001012588A1 (ja) サリチル酸アミド誘導体
WO2020043033A2 (zh) 一种乌帕替尼及其中间体的合成方法
FR2917413A1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
JPH06789B2 (ja) 新規セフエム化合物およびその製造法
JP2002510333A (ja) １，５−ジフェニルピラゾール誘導体
JPH05246980A (ja) β−オキソ−β−ベンゼンプロパンチオアミド誘導体
Nair et al. Folate analogs altered in the C9-N10 bridge region. 14. 11-Oxahomofolic acid, a potential antitumor agent
GOTO et al. An improved synthesis of N-hydroxyamino acids and their esters using (Z)-2-furaldehyde oxime
KR100259742B1 (ko) 메토트렉세이트 유도체
JP3207285B2 (ja) 新規メトトレキセート誘導体
JP4038245B2 (ja) 新規なフェナンスリジニウム誘導体
JP3100469B2 (ja) 乾癬治療剤
JPH07242670A (ja) ピロロ［３，２−ｅ］ピラゾロ［１，５−ａ］ピリミジン誘導体及びこれを含有する循環器系疾患治療剤
JP3145533B2 (ja) 新規メトトレキセート誘導体
JPH0533230B2 (enExample)
JPH0597841A (ja) イソクマリン誘導体
JP2980992B2 (ja) ６−ハロゲノ−２−オキサプレグナ−４，６−ジエン−３−オン化合物の製造方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20031016

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20041218

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20041218